Literature DB >> 33596111

Systemic Inflammatory Biomarkers as Surrogate Markers for Stage in Colon Cancer.

Server Sezgin Uludag1, Ahmet Necati Sanli1, Abdullah Kagan Zengin1, Mehmet Faik Ozcelik1.   

Abstract

BACKGROUND: This study aimed to investigate whether the systemic inflammatory parameters currently in use in staging the disease can be used as biomarker tests operated colon cancer patients. Neutrophil, lymphocyte, monocyte, platelet, neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), neutrophil/monocyte ratio (NMR), CRP, albumin, lymphocyte/CRP ratio, CRP/albumin ratio, and neutrophil/albumin ratio as systemic inflammatory biomarkers and prognostic nutritional index (PNI) were evaluated.
METHODS: This retrospective study included 592 patients. Patients with colon cancer in the cohort were divided into 2 subgroups: Tumor, nodes, metastases (TNM) stage 0, TNM stage 1, and TNM stage 2; early stage (n: 332) and TNM stage 3 and TNM stage 4; late stage (n: 260) colon cancer patients.
RESULTS: LDH (P < .001), NLR (P < .001), PLR (P < .05), CRP/albumin (P < .01), and neutrophil/albumin (P < .01) were significantly higher, while monocyte count (P < .05) and PNI (P < .01) were found to be significantly lower in late stage colon cancer patients than in early stage colon cancer patients. Moderate negative correlation was found between the PNI and the neutrophil/albumin ratio in late stage colon cancer patients (r: -.568, P < .001).
CONCLUSIONS: Our data suggest that high serum LDH, NLR, PLR, CRP/albumin, and neutrophil/albumin may be useful predictive markers for advanced stage in colon cancer. According to the receiver operating characteristic analysis results, CRP/albumin ratio can be used to discriminate early from late stage. Preoperative low monocyte count and PNI are associated with postoperative staging patients with colon cancer.

Entities:  

Keywords:  colon cancer; hematological indices; prognostic nutritional index; stage; systemic inflammatory biomarkers

Mesh:

Substances:

Year:  2021        PMID: 33596111     DOI: 10.1177/0003134821995059

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  The combined role of PET/CT metabolic parameters and inflammatory markers in detecting extensive disease in small cell lung cancer.

Authors:  Yao Hu; Jin Sun; Danming Li; Yangyang Li; Tiannv Li; Yuxiao Hu
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.